ICER Deems Potential ALS Drug Fairly Priced At No Less Than $9,100

By Gabrielle Wanneh / August 5, 2022 at 6:14 PM
The Institute for Clinical and Economic Review says the experimental ALS drug AMX0035 is comparable or better than current medications used to treat amyotrophic lateral sclerosis, and ICER estimates the fair price range at $9,100 to $30,600 annually. FDA plans to decide whether to approve AMX0035 by Sept. 29. ICER published on Thursday (Aug. 4) a revised evidence report on the clinical- and cost-effectiveness of AMX0035 and the oral ALS medication edaravone. The suggested fair-price range could change as more...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.